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Abstract
Background: VEGF-targeted therapy has become the mainstay of treatment for majority of mRCC patients. For most
patients, benefit is short-lived and therefore treatment remains palliative in intent. HD IL2 is an effective immunotherapy
treatment capable of durable remission in some patients but its unselected use has been difficult due to its modest
response rate and considerable adverse effects. Using set pathology criteria as a selection tool in clinical practice, we
have been able to show improved outcomes in our previous report. Here, we present an updated and extended report
of this treatment and seek to explore any pathological, clinical and treatment variables likely to predict better outcomes.
Methods: This is an extension of a previously reported clinical audit, which includes mRCC cases treated with HD IL2
between 2003 and 2013. Since 2006, tumour specimens of potential candidates were routinely reviewed prospectively
and stratified into Favourable or Other categories based on constitution of histological growth pattern, namely alveolar or
solid versus papillary and/or sarcomatoid architecture; clear cell versus granular cell cytoplasmic morphology. HD IL2 was
preferentially offered to patients with Favourable pathology. Outcome evaluation includes response rates, survival, and
treatment tolerance. Multivariate analysis was performed to explore potential prognostic and predictive factors.
Results: Among prospectively selected patients with Favourable pathology (n = 106), overall response rate was 48.1 %
(51/106) with CR rate of 21.6 % (23/106). Median OS was 58.1 months. Factors associated with significantly better
response and/or survival includes favourable pathology pattern, higher cycle 1 tolerance and lower number of
metastatic organ sites (<3). CAIX (Carbonic anhydrase 9) has prognostic value but is not predictive of response.
Toxicities were those expected of IL2 but were manageable on general medical wards, with no treatment-related
death. Importantly most complete responses were durable with 76 % (23/30) cases remained relapse-free
(median 39 months follow up) and 2 of the seven who relapsed had had long-term disease free survival
after resection of oligometastatic relapse.
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Conclusions: Our experience shows that HD IL2 remains an effective and safe treatment in well-selected
cases of mRCC. The result in this single-institution patient series confirms similar outcomes to our previously
reported retrospective series. Given the prospect of long-term remission, fit patients with Favourable histology
and low disease burden should be considered for HD IL2 in an experienced centre. Better understanding has
been gained from this in-depth analysis especially the examination of possible response predictors and strategies that
can improve treatment outcome.
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Introduction
Renal cell carcinoma (RCC) is associated with high mor-
tality, with approximately one third of patients diagnosed
with advanced or metastatic disease at presentation. Even
in patients with localised disease, relapse rate is as high as
40 % despite initial curative surgery and often with dis-
seminated distribution [1, 2]. There have been impressive
strides in the management of patients with mRCC using
targeted therapies in recent years. However, these treat-
ments remain palliative in intent with little prospect for
durable response [3–5]. The recent finding of survival
benefit with Nivolumab, a PD1 (Programmed cell death 1)
checkpoint inhibitor, compared to Everolimus in second
line or more setting [6] represents an exciting develop-
ment in the treatment paradigm of mRCC. The complete
response rate was, however, disappointing (1 %). Longer
term survival data including the extension of its use in
frontline setting as well as that of other similar agents and
combinations will inform us of the true potential of this
newly emerged treatment option.
High-dose Interleukin 2 (HD IL-2) is well documented
as an agent capable of achieving durable complete res-
ponse in patients with mRCC [7]. The response rate in
unselected populations is only modest with ORR of
14–20 % and CRR of 5–8 % [8–10]. In our centre, we
have placed a major emphasis on patient selection
using tumour morphology, which has been imple-
mented since its possible therapeutic relevance was re-
ported by Upton and group. This is likely the main
factor which has resulted in better outcome as demon-
strated in our first report [10]. Herein, we present the
updated and extended result of first-line HD IL2 treat-
ment in mRCC patients treated during a 10-year period
since 2003. We also aimed to explore any pathological,




At consideration of HD IL2 treatment, all patients were
assessed according to clinical selection criteria (Table 1).
Patients with active brain metastasis or those with an
autoimmune disorder requiring long-term steroids were
excluded. All patients had satisfactory baseline organ
function (Creatinine < 1.5 × ULN; ALT/AST < 3 × ULN).
A pathological classification was proposed by Upton et al.
in 2005 based on histological characteristic which ap-
peared to be predictive of IL2 treatment response [11].
Tumour of clear cell histology with no papillary fea-
tures, ≤ 50 % granular features, and ≥ 50 % alveolar
features were linked to higher responses. Our local
retrospective review was similar with regards to favourable
alveolar feature but a good proportion of responses were
seen among those considered unfavourable by Upton’s
criteria namely in those with limited focal papillary com-
ponent (<10 %), those with >50 % granular cells and those
with >50 % solid architecture. These were subsequently
adapted in our pathology selection criteria and have been
prospectively applied in our clinical practice since 2006.
As we are a referral center, all cases were initially diag-
nosed at peripheral centers. It is standard practice to carry
out central pathology review on all external histological
tissues by our resident pathologists prior to treatment
consideration and stratify into Favourable or Other
categories (Table 2).
Material from a nephrectomy specimen was preferred
but if this was not available, analysis of tumour from a
metastatic site was used. HD IL2 was offered to patients
in the Favourable category. Motivated patients with
Other pathology category type were offered treatment
after full informed discussion regarding risk and benefit
and other available treatment options at the time.
Note: Individual tumour morphology component ful-
filling the percentage threshold of our pathology criteria
was termed ‘favourable’, and ‘unfavourable’ if otherwise
(non-italic). For example, tumour with >50 % alveolar
Table 1 Clinical selection criteria for treatment of HD IL2
Clinical Selection criteria:
• Histological diagnosis of clear-cell type metastatic renal cell
carcinoma with measurable disease
• Performance status 0–1
• Prior-nephrectomy
• No concomitant use of steroids
• No evidence of active CNS involvement
• No history of coronary artery disease or normal stress
echocardiogram for patient older than 55-year-old of age.
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component is termed ‘favourable alveolar’. Likewise,
‘unfavourable granular and unfavourable papillary’ fea-
ture refer to >50 and >10 % of total tumour constituent
respectively.
Membrane carbonic anhydrase 9 (CAIX) expression
Membrane CAIX immunohistochemistry expression has
been suggested to be associated with better survival as
well as a potential predictor of HD IL-2 response [12–14].
To explore this potential property, CAIX expression
was assessed as part of prospective pathology review
but was not used as selection criteria. Paraffin-embedded
tissue sections were subjected to immunohistochemistry
using a mouse monoclonal antibody for CAIX (Novus
Biologicals, used at a dilution of 1/2000) and Menarini
Intellipath automated immunostainer using Menarini
detection system with a DAB chromogen. This was subse-
quently evaluated and the percentage of tumour cells
showing surface membrane positivity on the section was
provided.
High-dose interleukin 2
Each patient received intravenous Interleukin-2 at
600,000 unit/kg given over 15 min at a minimum of 8
hourly intervals up to a maximum of 14 doses as toler-
ated over a 5-day period. The 5-day treatment session
is repeated after a 10-day break. Treatment was delayed
or interrupted according to standard guidelines, and full
supportive medical measures were implemented as per
published guideline [15] and local protocol. Two 5-day
treatments constitute one cycle. Depending on therapeutic
benefit and tolerance, treatment was repeated every
12 weeks to maximum response. Further cycle(s) are
offered in the event of any response after cycle one.
Patients with stable disease (SD) may be considered for
further treatment especially in disease that was obviously
progressing before HD IL2. One further treatment cycle
was given after any best overall response (including
after CR) if possible. Treatment was discontinued in
event of unequivocal progressive disease (PD) or un-
acceptable toxicity – in addition, treatment was discon-
tinued for stable disease after 2 or more cycles as the
patient was unlikely to achieve a complete remission.
Written consent for treatment were obtained from
patients prior to start of treatment as required by
standard practice.
Outcome measurements and statistical analysis
The primary outcome measurement is overall response
rate. Secondary outcomes are survival, treatment tolerance
and toxicity. Treatment response was evaluated by CT
(computed topography) scan every 12 weeks using
RECIST criteria. Overall survival (OS) was calculated
from start of treatment to death or censored at time
last known to be alive respectively. Progression free
survival (PFS) was not an outcome measure in this re-
port due to 2 limitations. Firstly, patients who achieved
less than complete responses may have very variable
course of subsequent management. PFS in relation to
HD IL2 in such instances will be as a result of the
effects of both HD IL2 and their subsequent therapy.
Secondly, a significant number of patients were referred
from distant centres in the country and information re-
garding PFS, was not easily or accurately obtainable
within the resources of this clinical audit once patient’s
care has been transferred back to local centre for fur-
ther management. Last date of observation was 30th
October 2015. Response rate modelling was done using
logistic regression. Survival analysis was done using a
Cox proportional hazard model. Non-linearity of continu-
ous variables (CAIX and Cycle 1 dose) was investigated
using a penalized spline basis. All statistical analysis was
done using R version 3.2.0 (R Core Team, 2015) and the
survival package (v2.38-1, Therneau, 2015). Modeling was,
to some extent, exploratory and as there was no control
group any effects found here have the potential to be
affected by unmeasured confounders. As the treatment
population was considered fairly homogenous, the bias
on the dose response of this was assumed to be small.
Results
Patient population
This report included a total of 145 mRCC patients who
received HD IL2 in the first-line setting from 2003 to
2013 (Fig. 1). Seventy-three additional patients were in-
cluded since the conclusion of previous review in 2008.
Patients with Favourable pathology constitute approxi-
mately 12 % of all mRCC cases in our centre during this
period. Patient characteristic and demographic is as
outlined in Table 3. One patient had non-clear cell
tumour variant (Papillary type II) whereas the rest had
clear cell renal cell carcinoma. Median follow-up dura-
tion was 39 months. All patients had ECOG (Eastern
Cooperative Oncology Group) performance status 0–1
and had good or intermediate MSKCC (Memorial
Sloan-Kettering Cancer Centre) risk score. The com-
monest site of metastatic disease is lung (83.4 %)
followed by lymph node (49.7 %), intra-abdominal organ
(29.7 %), kidney recurrence (25.5 %), bone (16.6 %) and
other sites (11 %).
Table 2 Prospective pathology-based selection criteria
Type Histological features
Favourable Less than 10 % papillary histology, and at least one
favourable feature of:
• >50 % alveolar and or >50 % solid architecture
• <50 % granular cytoplasm or >50 % clear cell features
Other Histology features other than Favourable
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Following HD IL2, 55 % of patients in this series
were treated with VEGF-targeted therapies, 4 % en-
rolled into clinical trials, 2 % interferon and 22 %
active surveillance. Seventeen percent had no available
information.
Response rate and survival analysis
In total, there were 62 (42.8 %) responders in the entire
cohort of which 30 (20.7 %) were complete. Seventy-six
percent of CR remained relapse-free. ORR and CRR were
26.6 and 13.3 % prior to implementation of pathology se-
lection (N = 30), these rose to 48.1 and 21.6 % res-
pectively in the post-selection Favourable pathology
group (Aug 2006-Jul 2013 N = 106). Median overall sur-
vival (OS) of the entire cohort was 49.4 months but
was 58.1 months in the Favourable cohort (Fig. 2).
Survival performance stratified by response is as shown
in Additional file 1: Figure S1.
Fig. 1 Flow diagram showing cohorts of patient population
Table 3 Patient demographics and baseline clinical characteristics
Number (%)
Pre-selection N = 30 Post-selection N = 115 Overall N = 145
Age (median) 19–68 (52) 28–77 (54) 19–77 (54)
Male 23 (76.7) 82 (71.3) 105 (72.4)
Nephrectomy 26 (86.7) 115 (100) 141 (97.2)
MSKCC risk
Good 19 (63.3) 98 (85.2) 117 (80.7)
Intermediate 11 (36.7) 17 (14.8) 28 (19.3)
Poor 0 0 0
Heng risk
Favourable 7 (23.3) 60 (52.2) 67 (46.2)
Intermediate 19 (63.3) 47 (40.9) 66 (45.5)
Poor 4 (13.3) 8 (6.9) 12 (8.3)
Pathology type
Favourable 17 (56.7) 106 (92.2) 123 (84.8)
Other 13 (43.3) 9 (7.8) 22 (15.2)
No of met organ(s)
1 10 (33.3) 42 (36.5) 52 (35.9)
2 7 (23.3) 41 (35.7) 48 (33.1)
3 + 13 (43.3) 32 (27.8) 45 (31.0)
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Histological subgroups and response
We performed exploratory analysis on the various histology
features as specified by our pathology selection criteria to
study the response pattern further (Table 4). Response rate
was highest in Group A where all favourable features were
met (ORR 50.6 %; CRR 22.9 %). This cumulative benefit is
confirmed using multivariate analysis where the presence of
2–3 favourable features is associated with about 20 times
increase likelihood to respond to treatment than 0–1
(Fig. 3).
Notably, tumour with unfavourable alveolar but fa-
vourable solid features represented 31.5 % of all CRs in
group A. Despite presence of unfavourable granular
features in Group B which is the second largest sub-
group, CRR was comparable to Group A (21.1 %).
Independent of other histological criteria, patients
whose tumour showed any favourable alveolar and/or
solid features constituted highest proportion of CR
(28/30, 93.3 %).
Response rate in Other category was much lower
but there were 3 CRs. On review, 2 of the CRs both
had >10 % papillary constituent (30 %) but favourable
alveolar and granular features. Another CR was a non-
clear cell tumour variant (Type 2 papillary carcinoma).
There were 6 patients whose tumour contained sarco-
matoid architecture and responded to HD IL2 (of whom
2 were complete). All 6 had <10 % sarcomatoid con-
stituents and also had 2 other favourable histological
features. No response was seen at all with >10 % sar-
comatoid element. Response amongst patients whose
Fig. 2 Kaplan –Meier curve showing overall survival (months) of patients with Favourable pathology
Table 4 Response analysis based on sub-classification of histological features among clear cell tumours















Papillary <10 % ✔ ✔ ✔ NO NO ✔ NO
Alveolar or solid >50 % ✔ ✔ NO ✔ NO NO NO
Granular <50 % ✔ NO ✔ ✔ ✔ NO NO
ORR 42 (50.6) 13 (39.4) 3 (42.9) 2 (66.7) 0 (0) 0 (0) 1 (10.0)
CR 19 (22.9) 7 (21.2) 1 (14.3) 2 (66.7) 0 (0) 0 (0) 0 (0)
PR 23 (27.8) 6 (18.2) 2 (28.6) 0 (0) 0 (0) 0 (0) 1 (10.0)
SD 25 (30.1) 8 (24.2) 2 (28.6) 1 (33.3) 2 (66.7) 2 (40.0) 6 (60.0)
PD 16 (19.3) 12 (36.4) 2 (28.6) 0 (0) 1 (33.3) 3 (60.0) 3 (30.0)
Note: One patient with Type II Papillary carcinoma who achieved CR was excluded from this analysis
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tumours contained <10 % papillary features were simi-
lar compared to none (Table 5).
Membrane carbonic anhydrase 9 (CAIX) surface positivity
CAIX staining positivity was evaluable in 100 cases.
CAIX surface positivity was compared between the re-
sponder group (CR and PR) and non-responder group
(SD and PD). There was no difference in values between
the groups. The median value was 90 in both groups
and the distribution of values was similar (Fig. 4a) sug-
gesting the lack of correlation to response. However,
CAIX staining intensity appeared to have an incremental
prognostic impact in this treatment cohort as shown on
Fig. 4b.
Fig. 3 Forrest plots summarizing multivariate analysis and relationship between analyzed variables and (a) survival and (b) likelihood to response to IL2
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Cycle 1 dose number
There is an incremental survival benefit with higher
cycle 1 dose (between 12–20 total doses) (Fig. 5).
Interestingly, the survival benefit seemed to tail off
above 20 doses. Multivariate analysis also showed a
significant association between higher cycle 1 dose in-
tensity and any response (Fig. 3). There did not appear
to be a significant association with complete response
but this could be due to the smaller number of patients
who attained CR.
Number of metastatic organ sites involvement
High proportions (86.7 %, 26/30) of CR cases were in
patients with 1–2 number of organ sites (irrespective of
number of metastatic lesions in each organ) involve-
ment. The distribution of treatment response was similar
between those with 1 and 2 organ site involvements.
Therapeutic benefit of HD IL2 is significantly lower in
those with 3 or more metastatic organ sites (Fig. 6) The
inverse relationship between this variable and response
is shown in multivariate analysis. This variable also has a
clear impact on survival where patient with lesser number
of involved organ(s) fared significantly better with median
OS of 98, 43, 25 months for 1, 2, and 3 or more sites
respectively (p = 0.001).
Other variables and prognostic factors
Time interval from diagnosis (of kidney cancer) to start
of HD IL2 of less than 12 months, lower Fuhrman grading
both showed a possible link to response but this was not
statistically significant. There was no significant relation-
ship between IL2 response rates with age or MSKCC risk
group on univariate or multivariate analysis. Interestingly,
evidence of immune mediated toxicity may be associated
with response as, from our observation, 3 out of 4 patients
with myocarditis, 12 (6 PR 6 CR) out of 18 patients with
immune thyroiditis and 2/2 (both CR) with inflammatory
arthritis responded to IL2.
Surgery for oligometastatic disease
Three complete responders had surgery after disease re-
lapse, of which 2 remained disease-free and alive. Among
patients with partial response, 2/15 who had surgery for
residual oligometastatic disease remained disease – free
by the end of our observation period.
Treatment tolerance and toxicity
Treatment at our centre is administered on general on-
cology ward by experienced nurses, and local guidelines
are in place to manage routine toxicity. Median number
of cycles received in this series was 2 (Range 1–7).
Median total number of IL2 doses received was 27
(Range 6–141). Median number of doses during cycle 1
was 18 (range 6–25). Majority of patients completed
their treatment without significant complication. Most
acute phase toxicities were short- lived and completely
reversible.
All patients experienced anticipated grade 1–3 hypo-
tension, tachycardia and fever secondary to vascular
leak and cytokine release syndrome. Vascular leak syn-
drome was managed through the use of an intravenous
fluid replacement sliding scale based on recorded blood
pressure. Two patients developed a brief episode of
grade 4 hypotension requiring less than 24 h inotropic
support in intensive care unit.
Cardiac complications were seen in 15 patients. Four
patients developed treatment-related myocarditis as
proven by troponin rise and cardiac imaging. Treatment
was discontinued in all cases. All received cardiology
input with 2 patients receiving short-term supportive
treatment with a combination of beta-blockers and
angiotensin-converting enzyme inhibitors. Cardiac func-
tion returned to pre-treatment levels in 3/4 affected
patients. One patient has ongoing mild left ventricular
impairment. One patient, in addition to myocarditis
developed a secondary cardiac thrombus and embolic
stroke. This was managed conservatively with anticoagu-
lation and subsequently completely recovered with no
residual neurological deficit. One patient suffered an
acute coronary event with associated ECG changes and
troponin rise. This was successfully treated with coronary
angioplasty with no significant cardiac dysfunction. The
patient ultimately obtained a complete remission after
completing treatment with reduced dose IL2.
Ten patients developed supraventricular cardiac tachy-
arrhythmias with atrial fibrillation being the commonest
rhythm. Five patients required chemical cardioversion
with intravenous amiodarone whilst two others were
rate-controlled with a combination of digoxin and biso-
prolol. All patients reverted to normal sinus rhythm
within 48 h.
Eighteen patients developed immune-related thyroiditis.
One patient required short term beta-blockade for symp-
tomatic hyperthyroidism. All affected patients subse-
quently developed hypothyroidism requiring long-term
thyroid replacement.
Table 5 Response rate by proportion of papillary and sarcomatoid
features
None <10 % 10–30 % >30 %
Papillary N = 105 N = 27 N = 3 N = 8
ORR 43 (40.9) 14 (51.9) 2 (66.7) 1 (12.5)
CRR 20 (19.0) 6 (22.2) 2 (66.7) 0
Sarcomatoid N = 125 N = 12 N = 6 N = 2
ORR 56 (44.8) 6 (50.0) 0 0
CR 28 (22.4) 2 (16.7) 0 0
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Two patients developed grade 2 arthritis (seronegative),
both required short-term treatment with anti-inflammatory
and immunomodulatory treatment (cyclooxygenase-2 in-
hibitor and hyrdroxychloroquine). All inflammatory symp-
toms fully resolved in both cases and both were able to
complete treatment achieving durable complete responses.
One patient was, however, left with a finger deformity
which may require subsequent surgery. No patients died as
a direct consequence of HD IL2 treatment.
Discussion
The use of immunotherapy such as checkpoints inhibi-
tors is increasingly promising in the treatment of mRCC
in recent times. As we continue to explore the exciting
a)
b)
Fig. 4 a Plots and curves showing no association between CAIX and any response b survival curve showing significant relationship with increasing
CAIX expression
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Fig. 5 Relationship between cycle 1 dose intensity and survival probability
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application of newer agent such as Nivolumab, findings
from our review shows that HD IL2 remains an important
treatment option for this disease group. Despite being an
approved treatment option for mRCC for many years, up-
take of HD IL2 has been low due to the complexity of
therapy (requiring expert specialist management), its
significant toxicity and modest response rate in unse-
lected population. The rise of VEGF (Vascular Endothelial
Growth Factor)-targeted therapy with more predictable
efficacy and manageable side effects further reduced the
appeal of HD IL2 as first-line treatment in recent times.
Unfortunately, the inevitable tumour resistance associated
with targeted therapies meant that therapeutic intent re-
mains palliative for the majority.
The longstanding difficulty with HD IL2 has been the
lack of ability to pinpoint the subset of patients who can
benefit significantly from this treatment. There were
previous reports suggesting unfavourable IL2 outcome
in patients with higher disease burden (more than one
metastatic site), and short progression free interval of
less than 1 year [16]. Other observations possibly
associated with tumour response includes development
of thrombocytopenia [17], thyroid dysfunction [18], re-
bound lymphocytosis [19], and low monocytes and
granulocytes [20]. However, these are post-treatment
findings and therefore not helpful in pre-treatment patient
selection.
The plausible link between pathology and response
shown by Upton and colleague as well as our own re-
sults has increased optimism for this challenging treat-
ment option. The maintained high efficacy level in our
post-pathology selection cohort demonstrated by this
updated report continues to uphold this hypothesis. In
our case series, patients with tumours that met all three
pathology criteria fared extremely well, with 1 in 2
responding to treatment and 1 in 4–5 achieving CR.
This significant cumulative predictive benefit based on
higher number of favourable pathology criteria met was
shown in our multivariate analysis. We postulate that a
high level of alveolar features may be more important
than other features as previously discussed. We also
postulate that the presence of high solid pattern is a
favourable feature. In our experience, the presence of
papillary or sarcomatoid architecture of less than 10 %
is not necessarily unfavourable and should not be ex-
cluded if there were also other good histological fea-
tures. Based on our experience here, an upper limit of
30 % for papillary pattern may be considered an appro-
priate cut-off for future cases provided other features
are favourable.
We note the result from the prospective biomarker vali-
dation study by the Cytokine Working Group (SELECT)
which did not show any significant predictive value of
their proposed pathology selection tool also termed
Integrated Selection Model (ISM) [21]. Although the
response rate in SELECT was considered better (ORR
25 %) than historical result, this was nevertheless lower
than that predicted by the author (30–40 %) for the re-
quired statistical power of the trial. Interestingly, the
published information suggested only a very low pro-
portion (<10 %) with favourable (>50 %) alveolar archi-
tecture within the SELECT population, and based on
our findings showing correlation of this feature to res-
ponse, this could be one of the likely factor for the
lower than expected response rate in SELECT thus
could explain the lack of detectable effect. Importantly,
the ISM did not consider solid features to be a favourable
feature whereas our data convincingly show it to be one.
In addition, CAIX staining positivity was integrated in the
categorisation of ISM which, given its lack of predictive
Fig. 6 Bar chart showing distribution of responses according to number of metastatic organ sites
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value shown in our report, may also have an impact on
the overall outcome. Thus we feel the SELECT trial may
not have used optimal selection and the result from this
trial should not discourage further exploration and
utilisation of tumour pathology as predictive biomarker
in HD IL2.
The development of cancer immunotherapy has been
quite remarkable in the last 5 years where impressive
clinical benefits are seen across various tumour sites.
With rising healthcare cost and emphasis on persona-
lised care, there is an urgent need for a clinically relevant
biomarker to better select patients for a particular type
of treatment. Example biomarkers of interest currently
includes cell surface molecules such as PDL1, CD70 and
ICOS expression, tumour mutational load by exome
sequencing, as well as detailed immune cells analysis by
immune profiling or by TCR sequencing. As yet, none of
these has been validated for clinical use and some findings
have been highly inconsistent - this applies particularly to
PDL1 expression where the low level of expression and
the dynamic nature of its expression seem likely to limit
its value. However, the greater understanding of cancer
immunotherapy and the wider availability of molecular
immune assessment (including mutational analysis of the
tumour, TCR sequencing and potentially identification of
immunogenic targets) could potentially facilitate refine-
ment of our selection criteria to further improve the
therapeutic advantage. At present, based on our main-
tained high response rates in the post-selection era,
tumour morphology represents the most sensitive and
reliable predictor of IL2 response to date and may well have
similar predictive effect in other newer immunotherapies.
Additionally, there was evidence of response and sur-
vival benefit with higher number of IL2 doses received
during cycle 1 in this cohort. Similar effect was also pre-
viously observed by another group using HD IL2 in ma-
lignant melanoma [17]. This is a relatively independent
and thus useful variable compared to total number of
overall doses or treatment cycles which is inherently dic-
tated by response, i.e. patient who responded will naturally
do better and also continue to receive more treatment. It
is however possible that although all patients offered this
treatment were considered fit, there may be other likely
unaccounted variables that could have affected treatment
tolerance or even survival. There also seems to be a loss of
effect above 20 doses, although this could be a true effect,
there is a high degree of uncertainty above this threshold
due to the small number of patients receiving more than
20 doses. Even with such possible limitation, this remains
a convincing finding, and striving for maximal tolerance
within safe limits especially during first cycle appears to
be a justifiable strategy to improve outcome.
The number of metastatic organ sites also had a sig-
nificant bearing on response and survival in this patient
series. This is in keeping with previous reports, and may be
associated with increased heterogeneity allowing tumour
escape or immune suppressive effects of heavy tumour
burden [12, 16]. Limiting treatment only to those with 1–2
metastatic organ sites could avoid unnecessary toxicity in
those who are less likely to respond.
The treatment tolerance and toxicity was within ex-
pectation. Importantly, all adverse effects were reversible
(except thyroid dysfunction) and there has been no
treatment related death in this cohort. In keeping with
previous reports, development of immune related events
may be associated with better outcome as shown by ob-
servation of good proportion of responders among those
affected by these phenomena (thyroiditis, myocarditis
and arthritis).
Conclusion
Our analysis has unveiled interesting clinical and
treatment-related factors linked to better response and
survival, which could potentially be exploited to en-
hance outcomes further when using HD IL2. A good
proportion of well-selected patients can benefit from
durable treatment-free remission when complete response
is achieved, a unique advantage compared to all other cur-
rently available options which require continuous treat-
ment. Fit mRCC patients especially those with favourable
pathology and low disease burden should be referred for
consideration of HD IL2 at an experienced centre. Patient
selection based on tumour morphology has helped
achieve much-improved HD IL2 efficacy, and remains the
cornerstone of our practice. Effort to gain a better under-
standing of this interesting relationship through continued
translational research will refine and enhance the use of
immunotherapy in mRCC further. The use of HD IL2 in
combination with other immunomodulatory therapies
such as checkpoint inhibitors should also be explored to
investigate if higher rates of complete remission can be
obtained. We hope our experience and information shared
here will encourage oncologists to recommend this
therapy with renewed confidence.
Additional file
Additional file 1: Figure S1. (a) Survival curve showing overall survival
by response to HD IL2 and (b) Percentage of survival by response at 1, 3
and 5-years. (DOCX 80 kb)
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